Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Financing new drug development in ophthalmology.

G D Novack1

  • 1PharmaLogic Development Inc., San Rafael, California 94903, USA.

Journal of Glaucoma
|April 27, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ophthalmic drug delivery: development and regulatory considerations.

Clinical pharmacology and therapeutics·2009
Same author

Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization.

Journal of glaucoma·2001
Same author

Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2001
Same author

Submission of data sets to journals: what's the real issue?

Archives of ophthalmology (Chicago, Ill. : 1960)·2000
Same author

Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration.

American journal of ophthalmology·2000
Same author

Comparative irritancy study among retinoid creams and gels.

Journal of cutaneous medicine and surgery·1999

Securing funding is crucial for ophthalmic drug development. This article details key financial considerations throughout the drug discovery and development pipeline.

Area of Science:

  • Ophthalmology
  • Drug Development
  • Biotechnology

Background:

  • Previous work outlined the procedural aspects of ophthalmic drug development.
  • The drug discovery and development pipeline encompasses scientific method application, compound selection, biological evaluation, pharmaceutical formulation, clinical development, and regulatory approval.

Purpose of the Study:

  • To present key issues involved in funding ophthalmic drug discovery and development.
  • To highlight the financial aspects critical to advancing ocular therapeutics.

Main Methods:

  • Review of funding strategies in pharmaceutical research.
  • Analysis of financial challenges in ophthalmic drug development.
  • Discussion of investment models for biotechnology ventures.

Related Experiment Videos

Main Results:

  • Funding is a critical, often overlooked, component of the drug development lifecycle.
  • Various funding sources and financial hurdles exist at each stage of development.
  • Successful navigation of the funding process is essential for therapeutic innovation.

Conclusions:

  • Effective financial planning and resource management are paramount for successful ophthalmic drug development.
  • Understanding funding mechanisms is vital for researchers, investors, and regulatory bodies.
  • Addressing financial challenges proactively can accelerate the delivery of novel eye treatments.